1. Differences in and correlations between cognitive abilities and brain volumes in healthy control, mild cognitive impairment, and Alzheimer disease groups
- Author
-
Ul-Ho Jeong, Sung-Jun Park, Soon-Cheol Chung, Jung-Chul Lee, Young Chil Choi, Mi-Hyun Choi, Ji-Hye Baek, Dae-Woon Lim, Boseong Kim, Seon-Young Gim, Hyung-Sik Kim, and Beob-Yi Lee
- Subjects
medicine.medical_specialty ,Histology ,business.industry ,Cognition ,General Medicine ,Audiology ,medicine.disease ,030218 nuclear medicine & medical imaging ,White matter ,03 medical and health sciences ,0302 clinical medicine ,Boston Naming Test ,medicine.anatomical_structure ,Brain size ,Healthy control ,medicine ,Anatomy ,Alzheimer's disease ,Cognitive impairment ,business ,030217 neurology & neurosurgery ,Cognitive reserve - Abstract
The purpose of this study is to investigate differences in and correlations between cognitive abilities and brain volumes in healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) groups. The Korean Version of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD-K), which is used to diagnose AD, was used to measure the cognitive abilities of the study subjects, and the volumes of typical brain components related to AD diagnosis-cerebrospinal fluid (CSF), gray matter (GM), and white matter (WM)-were acquired. Of the CERAD-K subtests, the Boston Naming Test distinguished significantly among the HC, MCI, and AD groups. GM and WM volumes differed significantly among the three groups. There was a significant positive correlation between Boston Naming Test scores and GM and WM volumes. In conclusion, the Boston Naming Test and GM and WM brain volumes differentiated the three tested groups accurately, and there were strong correlations between Boston Naming Test scores and GM and WM volumes. These results will help to establish a test method that differentiates the three groups accurately and is economically feasible.
- Published
- 2016
- Full Text
- View/download PDF